United Therapeutics (NASDAQ:UTHR) CEO Sells $1,739,520.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $434.88, for a total transaction of $1,739,520.00. Following the transaction, the chief executive officer directly owned 130 shares in the company, valued at $56,534.40. This represents a 96.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $443.44 on Friday. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $444.57. The company has a market capitalization of $20.00 billion, a P/E ratio of 17.31, a P/E/G ratio of 6.68 and a beta of 0.66. The firm’s 50 day simple moving average is $353.34 and its two-hundred day simple moving average is $318.06.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. During the same period in the prior year, the firm earned $5.85 EPS. United Therapeutics’s revenue for the quarter was up 11.7% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on UTHR. Royal Bank Of Canada began coverage on shares of United Therapeutics in a report on Friday, September 26th. They issued an “outperform” rating and a $569.00 target price on the stock. Bank of America boosted their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $295.00 to $414.00 and gave the stock an “equal weight” rating in a report on Wednesday, September 3rd. Jefferies Financial Group boosted their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a report on Tuesday, July 8th. Ten equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $449.57.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently bought and sold shares of the business. Chung Wu Investment Group LLC bought a new stake in United Therapeutics in the second quarter worth $29,000. WealthCollab LLC grew its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its position in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the period. SVB Wealth LLC bought a new stake in United Therapeutics in the first quarter worth about $32,000. Finally, Geneos Wealth Management Inc. boosted its position in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the period. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.